ArticleFrontiers in oncology2021

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.

Naoki Matsumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.